ArticleNeurochemical research2026
Carboxypeptidase E Alleviates Depressive-Like Behaviors in Mice by Regulating BDNF/Nrf2 Axis-Mediated Ferroptosis.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carboxypeptidase E (CPE) may be a therapeutic target for depression. This study investigated the mechanistic insights into the possible regulatory role of CPE in ferroptosis in a mouse model of chronic unpredictable mild stress (CUMS)-induced depression. One week before CUMS exposure, mice received injections of adeno-associated virus-CPE. One week after CUMS induction, the Nrf2 inhibitor ML385 was administered. Behavioral tests were performed 3 weeks after CUMS induction. Ionized calcium-binding adapter molecule 1-positive cells and inflammatory cytokine levels in the CA1 region were assessed by immunofluorescence and ELISA. Hippocampal pathological and neuronal damage were evaluated using H&E and Nissl staining. Additionally, brain-derived neurotrophic factor (BDNF)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, ferroptosis markers, oxidative stress indices, glutathione peroxidase 4 (GPX4), and Fe2+ levels were measured using western blot, RT-qPCR, and biochemical assays. CPE overexpression alleviated CUMS-induced depression-like behaviors and hippocampal damage in mice. CPE overexpression reduced microglial activation, neuronal degeneration, and pro-inflammatory factors. It also attenuated oxidative stress by decreasing malondialdehyde, reactive oxygen species, and lactate dehydrogenase while elevating superoxide dismutase and glutathione-S-transferase activities. Mechanistically, CPE activated the BDNF/Nrf2 axis, increased GPX4 activity, suppressed acyl-CoA synthetase long chain family member 4 expression, and reduced iron accumulation. All protective effects of CPE overexpression were reversed by ML385. CPE overexpression activates the BDNF/Nrf2 signaling axis to inhibit ferroptosis, thereby reducing neuroinflammation and depression-like behaviors in mice. This work further clarifies the pathogenesis of depression, enriches pathophysiological theories, and provides key experimental evidence for early intervention and target development.
Indexed as
Identifiers
42560543What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.